These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15679171)

  • 1. Minimizing the potential for metabolic activation as an integral part of drug design.
    Evans DC; Baillie TA
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
    Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches for minimizing metabolic activation of new drug candidates in drug discovery.
    Kumar S; Mitra K; Kassahun K; Baillie TA
    Handb Exp Pharmacol; 2010; (196):511-44. PubMed ID: 20020275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
    Evans DC; Watt AP; Nicoll-Griffith DA; Baillie TA
    Chem Res Toxicol; 2004 Jan; 17(1):3-16. PubMed ID: 14727914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
    Baillie TA
    Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative structure-pharmacokinetics relationships and their importance in drug design, possibilities and limitations.
    Seydel JK
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):571-81. PubMed ID: 6513673
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of pharmaceutical profiling assays for optimization of drug-like properties.
    Di L; Kerns EH
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):495-504. PubMed ID: 16022186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug metabolism: an industrial research view of the future.
    Ober RE
    Drug Metab Rev; 1979; 10(2):315-9. PubMed ID: 551917
    [No Abstract]   [Full Text] [Related]  

  • 16. Addressing metabolic activation as an integral component of drug design.
    Doss GA; Baillie TA
    Drug Metab Rev; 2006; 38(4):641-9. PubMed ID: 17145693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring drug-protein interaction.
    Yang XX; Hu ZP; Chan SY; Zhou SF
    Clin Chim Acta; 2006 Mar; 365(1-2):9-29. PubMed ID: 16199025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Scheele memorial lecture 1989. Drug metabolism in the design and safety evaluation of new drugs.
    Parke DV
    Acta Pharm Nord; 1990; 2(4):231-48. PubMed ID: 2257083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.